Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

DYNAMIC-III: ctDNA split recurrence risk in stage III colon cancer, and de-escalation missed non-inferiority

In the phase 2/3 DYNAMIC-III trial published in Nature Medicine on October 20, 2025, 702 of 968 evaluable patients with stage III colon cancer were ctDNA-negative 5 to 6 weeks after surgery; 3-year recurrence-free survival was 87% if ctDNA-negative and 49% if ctDNA-positive, de-escalation in the ctDNA-negative group did not meet non-inferiority (85.3% versus 88.1%), and escalation in the ctDNA-positive group did not improve 2-year recurrence-free survival (51% versus 61%).

Nature Medicine